PharmaEngine Receives Approval Of US IND Application For A Phase II Study Of PEP02 (Liposome Irinotecan Injection) In Pancreatic Cancer

PharmaEngine, Inc. announced today that it has received approval of an Investigational New Drug (IND) application from the U.S. FDA for PEP02, a liposome formulation of irinotecan in a phase II study in patients with metastatic pancreatic cancer. Previous phase I data showed excellent pharmacokinetics, tolerability and efficacy of PEP02 in advanced solid tumor patients in a poster presented at 2008 ASCO Annual Meeting.

read more

Deceases & treatment

• Specific immunotherapy (xenovaccinotherapy) for cancer
  • Melanoma
  • Kidney cancer
  • Colorectal cancer
  • Gastric cancer
  • Lung cancer
  • Prostate cancer
  • Astrocytoma
• T-cell vaccination (autovaccinotherapy) for autoimmune diseases
  • Multiple sclerosis
  • Rheumatoid arthritis
• Regenarative therapy
• Clinical application of stem celltransplantation
• Cell transplantation (CT) in treating severe neurological disorders (general information)
  • Spinal cord injury
  • Craniocerebral (brain) injury (coma)
  • Craniocerebral (brain) injury (long-term consequences)
  • Brain stroke
  • Cerebral palsy
  • 100 point scale for assessing neurological status of a cerebral palsy patient
• Hepatic diseases
• Osteomielitis
• Arthrosis

Site search